<bill session="116" type="h" number="938" updated="2022-11-01T15:17:46Z">
  <state datetime="2019-04-03">REPORTED</state>
  <status>
    <unknown datetime="2019-04-03"/>
  </status>
  <introduced datetime="2019-01-31"/>
  <titles>
    <title type="display">BLOCKING Act of 2019</title>
    <title type="short" as="reported to house">BLOCKING Act of 2019</title>
    <title type="short" as="reported to house">Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019</title>
    <title type="short" as="introduced">BLOCKING Act of 2019</title>
    <title type="short" as="introduced">Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="S001180"/>
  <cosponsors>
    <cosponsor bioguide_id="C001103" joined="2019-01-31"/>
    <cosponsor bioguide_id="C001067" joined="2019-04-02"/>
    <cosponsor bioguide_id="C001119" joined="2019-03-25"/>
    <cosponsor bioguide_id="D000624" joined="2019-03-26"/>
    <cosponsor bioguide_id="E000215" joined="2019-03-26"/>
    <cosponsor bioguide_id="K000379" joined="2019-03-27"/>
    <cosponsor bioguide_id="M001163" joined="2019-03-27"/>
    <cosponsor bioguide_id="M001209" joined="2019-04-10"/>
    <cosponsor bioguide_id="M001187" joined="2019-05-01"/>
    <cosponsor bioguide_id="M001207" joined="2019-04-29"/>
    <cosponsor bioguide_id="P000034" joined="2019-03-26"/>
    <cosponsor bioguide_id="R000599" joined="2019-03-26"/>
    <cosponsor bioguide_id="R000515" joined="2019-03-27"/>
    <cosponsor bioguide_id="S001145" joined="2019-04-08"/>
    <cosponsor bioguide_id="V000133" joined="2019-03-29"/>
    <cosponsor bioguide_id="W000791" joined="2019-04-08"/>
  </cosponsors>
  <actions>
    <action datetime="2019-01-31">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-01-31" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-02-02">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-03-27">
      <text>Subcommittee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-03-27">
      <text>Forwarded by Subcommittee to Full Committee by Voice Vote .</text>
    </action>
    <action datetime="2019-04-03">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-04-03" state="REPORTED">
      <text>Ordered to be Reported by Voice Vote.</text>
    </action>
    <action datetime="2019-05-02">
      <text>Reported by the Committee on Energy and Commerce. H. Rept. 116-46.</text>
    </action>
    <calendar datetime="2019-05-02" calendar="Union" number="24">
      <text>Placed on the Union Calendar, Calendar No. 24.</text>
    </calendar>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Reporting, Markup, Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Reporting, Markup, Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="19" relation="unknown"/>
    <bill session="116" type="h" number="987" relation="unknown"/>
    <bill session="116" type="h" number="2700" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Competition and antitrust"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-10T15:23:29Z" status="Reported to House">Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 or the BLOCKING Act of 2019 

This bill modifies provisions related to market exclusivity for a generic drug.

Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.

The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.</summary>
  <committee-reports>
    <report>H. Rept. 116-46</report>
  </committee-reports>
</bill>
